Huxley Health introduces AERASYN Biotech and expands its leadership and intellectual-property platform.
The announcement introduced a dedicated biotechnology division focused on psychedelic-derived therapeutics and described expanded leadership and patent-protected capabilities.
Scientific and corporate highlights
- Dedicated AERASYN Biotech division focused on psychedelic-derived neurotherapeutics
- Leadership expansion supporting operations and platform development
- Technology coverage across discovery, therapeutic, delivery and process domains